BRUSSELS (dpa-AFX) - argenx SE (ARGX, ARGX.BR), a commercial-stage biopharma company on Thursday reported higher profits and sales for the three months ended September 30, 2025.
Profit for the period stood at $344.3 million or $5.18 per share as compared with $91.4 million or $1.39 per share in the corresponding period of the previous year.
Product net sales increased to $1.13 billion from $573 million in the year-ago period.
The financial guidance on the combined research and development and selling, general and administrative remains unchanged at approximately $2.5 billion.
The full-year 2025 financial results and fourth quarter 2025 business update would be issued on February 26, 2026.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
